A six-week statin trial left the speaker with muscle pain. Research shows statins can impair mitochondrial function at low doses, even without obvious symptoms. He argues patients need full disclosure of these metabolic risks alongside the cardiovascular benefits.
When I tried statins for 6 weeks, I developed muscle pains. These are called myalgias, and it's a common side effect. But what bothered me wasn't the pain itself, it's what it might mean. Studies in humans show that even at very low nanomolar concentrations, some statins can impair mitochondrial function—remember the powerhouse of the cell—even crippling complex IV of the electron transport chain, sometimes even when muscle symptoms aren't present. Now, that does not mean statins are bad medications. It doesn't mean that the risk-benefit doesn't lean positive for many patients, maybe even a majority of patients, certainly for secondary prevention. But to make fully informed personal decisions, we need these data. We need this information. Because at the end of the day, it's your body, your choice, and you have a right to the whole metabolic story. And right now, the dialogue broadly highlights the benefits while hiding the risks. Even if unintentionally. What do you think about that?
